Related Experiment Video
Updated: May 4, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations
Kristen R Nichols1, Michael W Demarco2, Michael D Vertin2
1Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Butler University, Indianapolis, Indiana ; Department of Pharmacy, Riley Hospital for Children, Indiana University Health, Indianapolis, Indiana ; Department of Pediatrics, Ryan White Center for Pediatric Infectious Disease, Indiana University School of Medicine, Indianapolis, Indiana. [Dr. DeMarco and Dr. Vertin were students at Butler University at the time of writing.].
Insights
Vancomycin and piperacillin/tazobactam at specified concentrations formed an initial precipitate upon mixing. This Y-site combination should be considered incompatible for co-infusion in pediatric patients.
Area of Science:
- Pharmacology
- Intravenous Drug Compatibility
- Pediatric Antibiotic Therapy
Background:
- Vancomycin and piperacillin/tazobactam are frequently used empiric antibiotics in hospitalized children.
- Existing data on the intravenous (IV) compatibility of these agents at various concentrations are inconsistent.
Purpose of the Study:
- To assess the Y-site compatibility of vancomycin at 10 mg/mL with piperacillin/tazobactam at 112.5 mg/mL.
- To provide critical compatibility data for safe co-administration in pediatric care.
Main Methods:
- Vancomycin (10 mg/mL) and piperacillin/tazobactam (112.5 mg/mL) solutions were prepared and stored refrigerated.
- Mixtures were visually inspected (color, clarity, particulates) and assessed for pH and turbidity using a Spec-20 turbidimeter.
- Evaluations were conducted immediately after mixing and at 30 minutes, 1 hour, and 4 hours post-mixing.
Main Results:
- An immediate, visible milky precipitate formed upon mixing vancomycin and piperacillin/tazobactam.
- This precipitate dissipated within 15 seconds.
- No further precipitate was observed, and turbidimetry and pH measurements showed no significant changes from baseline.
Conclusions:
- The combination of vancomycin 10 mg/mL and piperacillin/tazobactam 112.5 mg/mL exhibits immediate precipitation.
- Co-infusion via Y-site is not recommended due to observed incompatibility.
Background:
Vancomycin and piperacillin/tazobactam are common empiric antibiotics in hospitalized pediatric patients. Studies evaluating intravenous (IV) compatibility at various concentrations show inconsistent results.
Objective:
The objective of this study was to determine the Y-site compatibility of vancomycin 10 mg/mL and piperacillin/tazobactam 112.5 mg/mL.
Methods:
Vancomycin (10 g vial) was reconstituted using sterile water for injection (SWFI) and diluted with 5% dextrose in water (D5W) to a final concentration of 10 mg/mL in an evacuated IV bag. Piperacillin/tazobactam (40.5 g vial) was reconstituted and diluted with SWFI to a final concentration of 112.5 mg/mL (100 mg/mL piperacillin) in an evacuated IV bag. Both antibacterial stock solutions were then stored in a refrigerator at 4°C (39.2°F). Initial solution appearances, including color, clarity, and particulates, were documented. Diluted solutions were mixed in a quantity of 3 mL of each vancomycin and piperacillin/tazobactam in glass test tubes. Subsequent evaluation included pH assessment and visual evaluation with unaided eye, magnifying glass, high-beam light, and via Spec-20 turbidimeter. Solution mixtures were evaluated upon mixing and again at 30 minutes, 1 hour, and 4 hours after mixing.
Results:
Initial combination of vancomycin and piperacillin/tazobactam resulted in a milky precipitate, visible to the unaided eye, which dissipated 15 seconds after mixing. No precipitate was visualized via any method at any additional time point. Turbidimetry and pH readings did not demonstrate differences from baseline measurements.
Conclusions:
A combination of vancomycin 10 mg/mL and piperacillin/tazobactam 112.5 mg/mL demonstrated precipitation immediately upon mixing. Co-infusion of vancomycin and piperacillin/tazobactam via Y-site should be considered incompatible.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug Dosing: Infants and Children
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

